David Binion comments on Silent Crohn’s Disease (CD) in a recent Gastroenterology & Hepatology: Here’s the link —Silent Crohn’s Disease
- “Approximately one-quarter of patients with active disease are asymptomatic.” Some have termed these patients to have Silent CD.
- Biomarkers including blood tests (eg. CRP), fecal markers (eg. Calprotectin), imaging and endoscopy can reveal active disease in many asymptomatic patients. Conversely, about one-sixth of patients are “overreporters” who describe abdominal complaints without objective evidence of inflammation.
- “CRP elevation represents a more significant threshold of mucosal damage compared with endoscopic assessment.” “In our study, 37% of the silent Crohn’s disease cohort [with elevated CRP] at our center required hospitalization within 2 years compared with 7% of patients who felt well and had no elevation of CRP level.”
These findings reinforce the notion that mucosal healing in combination with symptoms is important at predicting long-term response to treatment. A commonly-used physician global assessment may miss silent CD.
Bottomline: In those with “inactive” CD, obtaining a CRP (and possibly a fecal calprotectin) will improve detection of silent CD.
Related blog posts:
Pingback: What We Know Now: Therapeutic Drug Monitoring for Inflammatory Bowel Disease | gutsandgrowth
Pingback: PCDAI -Not Good Enough | gutsandgrowth
Pingback: Final Tweets from #NASPGHAN15 | gutsandgrowth
Pingback: Disease extent and need for higher infliximab dosing | gutsandgrowth